Reuters: Health
Tocagen Inc said on Thursday its experimental treatment did not prove effective in extending life of brain cancer patients in a late-stage study, sending shares down 68%.
Tocagen's brain cancer treatment fails late-stage study, shares slump
Tocagen's brain cancer treatment fails late-stage study, shares slump
Reuters: Health
Tocagen Inc said on Thursday its experimental treatment did not prove effective in extending life of brain cancer patients in a late-stage study, sending shares down 68%.
Reuters: Health
Tocagen Inc said on Thursday its experimental treatment did not prove effective in extending life of brain cancer patients in a late-stage study, sending shares down 68%.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment